SG11202102111SA - Cell-based clostridal neurotoxin assays - Google Patents

Cell-based clostridal neurotoxin assays

Info

Publication number
SG11202102111SA
SG11202102111SA SG11202102111SA SG11202102111SA SG11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA SG 11202102111S A SG11202102111S A SG 11202102111SA
Authority
SG
Singapore
Prior art keywords
clostridal
cell
neurotoxin
assays
neurotoxin assays
Prior art date
Application number
SG11202102111SA
Inventor
Keith Foster
Matthew Beard
Jeremy Changyu Yeo
Frederic Andre Jean Bard
Pei Ling Felicia Tay
Original Assignee
Ipsen Biopharm Ltd
Institute Of Molecular And Cell Biology Biomedical Sciences Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd, Institute Of Molecular And Cell Biology Biomedical Sciences Institutes filed Critical Ipsen Biopharm Ltd
Publication of SG11202102111SA publication Critical patent/SG11202102111SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0619Neurons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202102111SA 2018-09-28 2019-09-27 Cell-based clostridal neurotoxin assays SG11202102111SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201815870 2018-09-28
PCT/GB2019/052734 WO2020065338A1 (en) 2018-09-28 2019-09-27 Cell-based clostridal neurotoxin assays

Publications (1)

Publication Number Publication Date
SG11202102111SA true SG11202102111SA (en) 2021-04-29

Family

ID=68136432

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102111SA SG11202102111SA (en) 2018-09-28 2019-09-27 Cell-based clostridal neurotoxin assays

Country Status (12)

Country Link
US (1) US20220357314A1 (en)
EP (1) EP3856923A1 (en)
JP (1) JP2022512565A (en)
KR (1) KR20210098436A (en)
CN (1) CN113015812A (en)
AU (1) AU2019350528A1 (en)
BR (1) BR112021005774A2 (en)
CA (1) CA3111674A1 (en)
EA (1) EA202190892A1 (en)
MX (1) MX2021002726A (en)
SG (1) SG11202102111SA (en)
WO (1) WO2020065338A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061429T2 (en) * 2016-07-08 2023-06-28 Childrens Medical Center A novel botulinum neurotoxin and its derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2264052A3 (en) 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
DE102004043009A1 (en) 2004-09-06 2006-03-23 Toxogen Gmbh Transport protein for introducing chemical compounds into nerve cells
DE102005019302A1 (en) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier for targeting nerve cells
JP5764550B2 (en) 2009-04-14 2015-08-19 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド Genetically engineered botulinum neurotoxin
WO2012047325A2 (en) * 2010-06-11 2012-04-12 Synaptic Research, Llc N-end rule protease activity indication methods and uses thereof
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
CN103958747B (en) * 2011-09-29 2017-03-01 塞尔斯纳普有限责任公司 Compositionss for toxigenicity test and method
AU2013331771B2 (en) * 2012-10-16 2018-08-02 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
US10634683B2 (en) * 2014-11-21 2020-04-28 Merz Pharma Gmbh & Co. Kgaa Methods for the determination of the biological activities of neurotoxin polypeptides
EP3447120B1 (en) * 2016-05-24 2021-06-23 Nippon Telegraph And Telephone Corporation Three-dimensional thin film structure having microparticles enclosed therein and method for manufacturing same
HUE061429T2 (en) 2016-07-08 2023-06-28 Childrens Medical Center A novel botulinum neurotoxin and its derivatives

Also Published As

Publication number Publication date
KR20210098436A (en) 2021-08-10
JP2022512565A (en) 2022-02-07
AU2019350528A1 (en) 2021-04-15
CN113015812A (en) 2021-06-22
CA3111674A1 (en) 2020-04-02
MX2021002726A (en) 2021-07-16
EA202190892A1 (en) 2021-07-05
WO2020065338A1 (en) 2020-04-02
BR112021005774A2 (en) 2021-07-06
EP3856923A1 (en) 2021-08-04
US20220357314A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
EP3662259A4 (en) Colorimetric assays
EP3212757A4 (en) Microfluidic device for cell-based assays
EP3602218A4 (en) Predictive integrity analysis
IL277687A (en) Colocalization-by-linkage sandwich assays
IL266857A (en) Antibody assay
GB201807409D0 (en) Assay
GB201900893D0 (en) Cell contamination assay
GB201819187D0 (en) Assay
GB2579810B (en) Assay Analysis
SG11202102111SA (en) Cell-based clostridal neurotoxin assays
GB201820863D0 (en) Screening assay
IL287629A (en) Assays
GB201815278D0 (en) Assay
GB201809338D0 (en) Cell contamination assay
GB201809337D0 (en) Cell contamination assay
GB201809336D0 (en) Cell contamination assay
GB201801036D0 (en) Cell contamination assay
GB201801035D0 (en) Cell Contamination Assay
GB201801034D0 (en) Cell contamination assay
GB201914959D0 (en) Assay
GB201911397D0 (en) Assay
GB201911182D0 (en) Assay
GB201910477D0 (en) Assay
GB201817024D0 (en) Serum biomarkers
GB201816764D0 (en) Serum biomarkers